个人简历

2006年获得神经药理学博士学位，旋即赴美国约翰霍普金斯大学神经科学系从事博士后研究工作，主要开展离子通道新型调制剂的发现和分子调控机制研究。2010年回国工作，主要开展与神经系统疾病相关的离子通道药理学研究和药物发现。

研究领域

以癫痫、疼痛等神经系统重大疾病相关离子通道为中心，推进离子通道新功能、新机制、新靶点研究，发现新型离子通道调制剂，开发靶向离子通道的新药。中山药物创新研究院的课题组在开展化学小分子药物研发的同时，更加注重发展基因编辑、核酸药物等新兴疗法并用于重大神经系统疾病的治疗。

研究成果

建立系统性完备的离子通道药物研发平台，发现新型离子通道及期调节剂；通过高通量筛选、合理药物设计、结构改造等多种技术手段，与药物化学家合作研发的两个作用机制完全不同的抗癫痫候选药物，均已进入临床试验；开展包括hERG检测在内的多种形式的服务及合作，已为全国多达30项新药申报提供检测服务。发表通讯作者SCI论文44篇，授权专利7项。 2018年获得国家杰出青年科学基金资助，并入选创新人才推进计划中青年科技创新领军人才，2019年入选国家百千万人才工程。承担国家新药创制重大专项、973课题、基金委国际合作重点项目、基金委面上项目等多项国家项目以及中科院先导专项、药物创新研究院自主部署科研项目以及上海市科技支撑项目。

代表性论著（*：通讯作者）

1. Sun X, Zhang X, Ren X, Sun H, Wu L, Wang C, Ye X, York P, Gao Z, Jiang H*, Zhang J*, Yin X*: Multiscale Co‐reconstruction of Lung Architectures and Inhalable Materials Spatial Distribution. Advanced Science 2021:2003941.

2. Xie ZQ#, Tian XT#, Zheng YM#, Zhan L, Chen XQ, Xin XM*, Huang CG*, Gao ZB*: Antiepileptic geissoschizine methyl ether is an inhibitor of multiple neuronal channels. Acta Pharmacol Sin 2020, 41(5):629-637.

3. Wang JT#, Zheng YM#, Chen YT, Gu M, Gao ZB*, Nan FJ*: Discovery of aryl sulfonamide-selective Nav1.7 inhibitors with a highly hydrophobic ethanoanthracene core. Acta Pharmacol Sin 2020, 41(3):293-302.

4. Chi H, Zhang X, Chen X, Fang S, Ding Q, Gao Z*: Sanguinarine is an agonist of TRPA1 channel. Biochemical and biophysical research communications 2020, 534.

5. Zhang X#, Yin X#, Zhang J#, Li A, Gong H, Luo Q, Zhang H*, Gao Z*, Jiang H*: High-resolution mapping of brain vasculature and its impairment in the hippocampus of Alzheimer's disease mice. National Science Review 2019, 6.

6. Wang L, Qiao GH, Hu HN, Gao ZB*, Nan FJ*: Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity. ACS Med Chem Lett 2019, 10(1):27-33.

7. Tian F, Qiu Y, Lan X, Li M, Yang H, Gao Z*: A Small-Molecule Compound Selectively Activates K2P Channel TASK-3 by Acting at Two Distant Clusters of Residues. Molecular Pharmacology 2019, 96:mol.118.115303.

8. Liao P#, Qiu Y#, Mo Y#, Fu J#, Song Z#, Huang L#, Bai S, Wang Y, Zhu JJ, Tian F, Chen Z, Pan N, Sun EY, Yang L, Lan X, Chen Y, Huang D, Sun P, Zhao L, Yang D, Lu W, Yang T, Xiao J, Li WG, Gao Z, Shen B, Zhang Q, Liu J, Jiang H, Jiang *R, Yang H*: Selective activation of TWIK-related acid-sensitive K(+) 3 subunit-containing channels is analgesic in rodent models. Sci Transl Med 2019, 11(519).

9.  Li YF, Zheng YM, Yu Y, Gan Y*, Gao ZB*: Inhibitory effects of lappaconitine on the neuronal isoforms of voltage-gated sodium channels. Acta Pharmacol Sin 2019, 40(4):451-459

10. Zheng YM, Wang WF, Li YF, Yu Y*, Gao ZB*: Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. Acta Pharmacol Sin 2018, 39(4):587-596.

11. Qiu B#, Xia B#, Qingtong Z, Lu Y, He M, Hasegawa K, Ma Z, Zhang F, Gu L, Mao Q, Wang F, Zhao S, Gao Z*, Liao J*: Succinate-acetate permease from Citrobacter koseri is an anion channel that unidirectionally translocates acetate. Cell research 2018, 28.

12. Ding Q, Fang S, Chen X, Wang Y, Li J, Tian F, Xu X, Attali B, Xie X, Gao Z*: TRPA1 channel mediates organophosphate-induced delayed neuropathy. Cell discovery 2017, 3:17024.

13. Yue JF, Qiao GH, Liu N, Nan FJ*, Gao ZB*: Novel KCNQ2 channel activators discovered using fluorescence-based and automated patch-clamp-based high-throughput screening techniques. Acta Pharmacol Sin 2016, 37(1):105-110.

14. Xia B, Fang S, Chen X, Hu H, Chen P, Wang H*, Gao Z*: MLKL forms cation channels. Cell Res 2016, 26(5):517-528.

15. Lan X#, Fan C#, Ji W, Tian F, Xu T*, Gao Z*: Grafting voltage and pharmacological sensitivity in potassium channels. Cell Res 2016, 26(8):935-945.